




VR588 demonstrates a pharmacokinetic
profile suitable for development as an inhaled
treatment. Functional, cellular and cytokine-
related outcomes in the HDM model suggest
that inhaled VR588 may represent a novel
treatment for asthma.
Janus kinases regulate the expression of
multiple cytokines involved in asthma.
VR588 is a potent and selective pan-JAK
inhibitor suited to delivery via inhalation.
The objective of this study was to determine
the pharmacokinetic profile of VR588 and its
in-vivo efficacy in a murine chronic HDM
model of asthma.
VR588 pharmacokinetics were measured following
intranasal (i.n.) administration (1.5 to 50mg/kg,
n=6 per group) to male BALB/c mice and compared
with an oral dose of 15mg/kg. Lung and plasma
samples were analysed by LC-MS/MS at
predetermined time points between 5 minutes
and 24hrs post dosing.
HDM extract (25µg) was given 5 days/week for 3
weeks with multiple VR588 doses (1.5 to 7.5
mg/kg, i.n.) given 1hr prior to each HDM exposure;
a separate group were administered VR588
(7.5mg/kg i.n., n=8) only during the last week of
HDM treatment. Comparison was made with oral
tofacitinib (15mg/kg) and fluticasone propionate
(1.5mg/kg i.n.). Airway hyperresponsiveness (AHR)
to acetylcholine was assessed 24hrs after the last
HDM exposure; bronchoalveolar lavage (BAL) fluid
was obtained and differential cell counts, STAT
activation and cytokine expression measured.
The selective pan-Janus kinase (JAK) inhibitor VR588 
demonstrates potent anti-inflammatory activity in a murine 
chronic house dust mite (HDM) model of asthma.
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Intranasal VR588 rapidly (5 minutes) achieved
lung levels which were maintained for 24
hours in a dose-related manner. Plasma levels
were approximately 1,000 fold lower.
Results I
All VR588 doses significantly reduced BAL
total cell count with an effect on macrophage,
neutrophil, lymphocyte and eosinophils
counts (*p<0.05, **p<0.01 and ***p<0.001
vs. saline control. #p<0.05, ##p<0.01 and
###p<0.001 vs. HDM group).
VR588 attenuated HDM-induced expression
of cytokines such as KC, IL-4, IL-5 & IL-17
compared with saline control (*p<0.05,
**p<0.01 and ***p<0.001 vs. saline control.
#p<0.05, ##p<0.01 and ###p<0.001 vs. HDM
group).
Results IV
VR588 significantly reduced HDM-induced
AHR to a greater extent compared to FP and
ToF (*p<0.05, **p<0.01 vs. saline).
# # # VR588, FP, ToF vs. HDM group
Results II
HDM induced phosphorylation of STAT 3 was
reduced by all VR588 doses at 24hrs at a
magnitude at least comparable to that
observed with fluticasone and tofacitinib.
Results V
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